On the recordOctober 25, 2023
According to a recent GAO report, despite representing just two percent of the review boards, these commercial IRBs now review over half of studies involving investigational new drugs.
Source
congress.govEditor's note · Context
Warren cites a GAO report on the dominance of commercial IRBs in drug trials.
Share & report
More from William Warren
Sep 24, 2025
If Nexstar or Sinclair traded the censorship of a critic of the administration for official acts by the Trump administration, your companies are not only complicit in an alarming trampling of free speech but also risk running afoul of…
Oct 2, 2025
Let’s be clear: the jobs data scheduled to come out this Friday has undoubtedly been collected and the President must release it.
Other voices in this conversation
